ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Overhead Caused By Outreach, Other Federal Programs Threatens Cancer Centers, Durant Contends

November 5, 1976

Senate Subcommittee Agrees On $1.188 Billion NCI Budgt for FY 1985, $110 Million Increase Over ‘84

June 29, 1984

FDA News: FDA Lifts Clinical Hold On CTI’s Tosedostat

January 31, 2014

Moses To Lead AACI.

October 19, 2001

NCI Programs: Contract Awarded For Geographic Information System

May 14, 1999

FDA carries Action On Two Cancer Drugs Over To 1996

January 5, 1996